Immunomedics, Inc. (NASDAQ:IMMU)

CAPS Rating: 4 out of 5

A biopharmaceutical company focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases.

Results 1 - 20 of 33 : 1 2 Next »

Recs

0
Member Avatar pchop12316 (82.11) Submitted: 7/31/2015 10:41:44 AM : Outperform Start Price: $2.05 IMMU Score: +3.30

great buy-in opportunity on quality firm

Recs

1
Member Avatar zzlangerhans (99.69) Submitted: 7/30/2015 10:42:23 PM : Outperform Start Price: $2.07 IMMU Score: +2.38

Lately my CAPS score and my real life accounts have been taking a drubbing as some of my long-term favorite stocks have taken a drubbing while a number of my most overvalued shorts have become twice as overvalued. One of the most painful aspects of this losing streak is my complete inability to predict the market reaction to binary catalysts. I was surprised to see Transition being crushed so viciously on the failure of its highly dubious Alzheimer's drug, which I had thought was pretty much written off, yet Alcobra was hardly dented by the third trial failure in a row of their only drug in clinical trials.

Another stock I was surprised to see being crushed recently was Immunomedics, which finally announced the failure of the EMBODY trials of epratuzumab for lupus. After almost five years in which the company hardly discussed the ongoing trials, if they mentioned them in the conference calls as well, I had concluded it was virtually certain EMBODY would fail. The only question was if Immunomedics would bother to report it or if they would sweep the program under the rug. Even if I had been tracking the company closely, I wouldn't have bought puts since I thought the failure would barely dent the share price. Naturally, the stock was decimated almost 50% when the trial results were reported earlier this week.

In my mind, the real meat of the Immunomedics story are the antibody-drug conjugates IMMU-130 and IMMU-132. IMMU-132 in particular showed encouraging results in solid tumors in an interim analysis at ASCO, and management has stated they are seeking a partner and FDA feedback on registrational trials. Interim data for IMMU-130 in metastatic colon cancer wasn't as impressive, and I'm very skeptical about the prospects for cilvatuzumab. Nevertheless, a strong partnership for IMMU-132 could start a new fire under the stock if that event occurs in the near future. Otherwise, there's still room for decay as Immunomedics will likely have less cash than debt once the next quarterly results are reported.

Recs

0
Member Avatar a410traveler (48.20) Submitted: 4/23/2015 11:37:31 AM : Outperform Start Price: $4.12 IMMU Score: -48.35

Strong pipeline of drugs

Recs

0
Member Avatar TerryFool (63.24) Submitted: 3/25/2014 5:50:51 AM : Outperform Start Price: $3.88 IMMU Score: -58.03

BUY@ 4.0 TP 7

Recs

0
Member Avatar TerryHoodSr (75.52) Submitted: 3/24/2014 6:51:27 PM : Outperform Start Price: $4.07 IMMU Score: -59.31

SPEC BUY@ 4.1 TP 7

Recs

0
Member Avatar richienorker (< 20) Submitted: 9/27/2013 11:29:32 AM : Outperform Start Price: $6.29 IMMU Score: -90.56

Feel that new drugs will push this stock higher in next few minths.

Recs

0
Member Avatar rocknpopstocks (< 20) Submitted: 1/28/2011 12:47:04 PM : Outperform Start Price: $3.26 IMMU Score: -98.77

Could show solid growth Sling'n them legal life savers and thrills.

Recs

0
Member Avatar LuckyShad (75.31) Submitted: 5/25/2010 3:52:30 PM : Outperform Start Price: $3.29 IMMU Score: -130.73

There were 50 items in your list. Here they are in random order:

1 APOL 2S
CBPO (ALREADY PICKED)
2 AFAM 5S
3 IMMU 3*
4 TNDM 5*
AMED
RAI
VPHM
SNTS
CNU
SOLR
IDCC
HRB
UNTD
UEPS
CHKE
SOHU
DECK
OSK
PDLI
NSR
CBI
LO
CYTK
TTT
JCOM
MHP
CHOP
EME
RGR
CSKI
RTN
UIS
ENDP
PRSC
IPXL
VALU
USMO
ELNK
GME
FWLT
CF
ARO
TSRA
MRX
CBST
PPD
DLX
FLR
LIWA
Timestamp: 2010-05-25 19:32:44 UTC

Recs

0
Member Avatar BullishBilly (36.78) Submitted: 4/10/2010 6:35:07 PM : Outperform Start Price: $3.57 IMMU Score: -116.06

Relative to its industry, it has a high earnings yield. Also, strong earnings per share growth is predicted this year.

Recs

0
Member Avatar rasta999 (< 20) Submitted: 3/23/2010 5:50:51 PM : Outperform Start Price: $3.49 IMMU Score: -118.99

drugs in pipeline

Recs

0
Member Avatar connorsdad418 (< 20) Submitted: 3/10/2010 5:40:53 PM : Outperform Start Price: $3.50 IMMU Score: -122.51

timeframe is a bit long here...i actually believe IMMU will see significant PPS increases about a year sooner but there will be big gains in that four year period overall. greatly situated in the sectors that will see obscene amounts of private and public cash thrown at it, specifically immunotherapy and cancer treatments.

Recs

0
Member Avatar itistime2save (< 20) Submitted: 3/3/2010 10:41:56 PM : Outperform Start Price: $3.37 IMMU Score: -123.84

adding to my position Any opinions?

Recs

0
Member Avatar mrsrmc (< 20) Submitted: 10/16/2009 5:22:58 PM : Outperform Start Price: $4.95 IMMU Score: -149.61

There is a vast underreported and researched arm of health care - auto immune dieases and pain care. Plus factopr in "health care reform" mutant viruses running away with headlines, I think this will be one of the companies perking up into the limelight.

Recs

0
Member Avatar goneskuba (53.26) Submitted: 8/31/2009 4:40:45 PM : Underperform Start Price: $5.39 IMMU Score: +167.50

phase ii trials are a long long way away from late phase iii trials...its appears that HGSI might have gotten the lead on a monclonal SLE drug (HGSI might even get the green light and get fast tracked thru the FDA approval process and to market after this november when they release their data)...it seems that gsk might have actually lost out!!!

All this leaves IMMU in the dust...and one drug a company does not make, esp a drug to market coming in second

Recs

0
Member Avatar stocoptions (< 20) Submitted: 8/27/2009 9:46:31 PM : Outperform Start Price: $6.50 IMMU Score: -169.66

good technology

Recs

0
Member Avatar coachinfool (< 20) Submitted: 8/23/2009 8:18:31 AM : Outperform Start Price: $4.12 IMMU Score: -152.55

No longer using cash to fuel its Bunson burners and has promising results in the pipeline and a fast track approval for hPAM 4.

Recs

0
Member Avatar idahoranch (< 20) Submitted: 6/14/2009 3:08:54 PM : Outperform Start Price: $2.53 IMMU Score: -142.08

Immunomedics hPAM4 antibody for pancreatic cancer is under the radar, but nearly 50% of patients treated in the phase l trial are having good responses with tumors shrinking and the quality of life during and after treatment has been very good, unlike with most Chemo's. This could be a huge home run. The company has stated they have no intention to license this product out.

Also, UCB will be coming out with data for Epratuzumab in their dosing trials for SLE (lupus) where they are trying to find the right dose for the phase lll trials. Every trial done so far has shown Epratuzumab to have efficacy in SLE. Another sleeper.

Recs

0
Member Avatar hmcnamee (< 20) Submitted: 5/12/2009 1:32:56 AM : Outperform Start Price: $1.81 IMMU Score: -114.64

IMMU has moved to profitability over the past two quarters primarily based on the Nycomed deal. They continue to report promising results on a number of other trials for treatments of different forms of cancer. Immunomedics good cash position should provide sufficient funding in the current economic environment. Finally, the company holds an impressive portfolio of patents which seem to be undervalued by the market.

Recs

0
Member Avatar propertiusthesec (< 20) Submitted: 5/27/2008 5:19:12 PM : Outperform Start Price: $2.73 IMMU Score: -79.13

This biotech firm has a portfolio of marketable auction securities that it is selling as opportunities arise; patents and favorable phase two and three tests for drugs that improve the efficacy and reduce the deleterious effects of cancer drugs. It is currently trading above $2.60, and brokerage analysts project that it will trade at $7 within a year. It does seem to be taking a long time for management to negotiate royalty deals with major drug companies, which are said to be interested.

Recs

0
Member Avatar cancunjake (21.72) Submitted: 5/23/2008 5:08:02 PM : Outperform Start Price: $2.36 IMMU Score: -67.08

why not biotechs great place to put money . the use little gasoline

Results 1 - 20 of 33 : 1 2 Next »

Featured Broker Partners


Advertisement